2009
Molecular markers and death from prostate cancer.
Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Annals Of Internal Medicine 2009, 150: 595-603. PMID: 19414838, DOI: 10.7326/0003-4819-150-9-200905050-00005.Peer-Reviewed Original ResearchConceptsProstate-specific antigen levelProstate cancerLong-term riskAntigen levelsMicrovessel densityMedian prostate-specific antigen levelIncreased long-term riskVeterans Affairs Healthcare SystemIncident prostate cancerObservational cohort studyProportional hazards analysisTime of diagnosisHigher microvessel densityVeterans Health AdministrationBcl-2Years of ageProstate cancer biopsiesClinical care recordsClinical characteristicsCohort studyPatient ageMedian ageComorbid conditionsHistologic gradeResidual confounding
2002
Histopathologic Features of Genetically Determined Ovarian Cancer
Shaw P, McLaughlin J, Zweemer R, Narod S, Risch H, Verheijen R, Ryan A, Menko F, Kenemans P, Jacobs I. Histopathologic Features of Genetically Determined Ovarian Cancer. International Journal Of Gynecological Pathology 2002, 21: 407-411. PMID: 12352190, DOI: 10.1097/00004347-200210000-00011.Peer-Reviewed Original ResearchConceptsInvasive serous carcinomasOvarian carcinomaSilverberg gradeGermline mutationsHistologic typeSerous carcinomaNuclear gradeGOG grade 3High histologic gradeBRCA1/BRCA2Serous histologyGynecologic pathologistsHistologic featuresHistopathologic featuresBRCA carriersHistologic gradeBRCA mutationsOvarian cancerArchitectural gradeBRCA2 mutationsGrade 3Germline BRCA1CarcinomaMutation statusControl group